INTRODUCTION
The meniscus in the knee joint is a crescent-shaped connective tissue between the distal femoral and proximal tibial condyles that provides structural congruence and absorbs mechanical forces (1) . Meniscus injuries are treated with meniscus resection with or without a cadaveric meniscus graft (2) . Meniscectomy exposes femoral and tibial condyles to excessive wear and is a highly predisposing factor for osteoarthritis, the most prevalent cause of chronic disabilities among heart failure, spinal cord injuries, respiratory disorders, and stroke (1) . Meniscus replacement with allografts or cadaveric tissue suffers from limited graft availability, pathogen transmission, immune rejection, and anatomical mismatch (1, 2) . Injuries and diseases of all fibrocartilage tissues, including the meniscus, the tendon-bone junctions, the intervertebral discs of the spine, and the temporomandibular joint, fail to heal spontaneously, leading to collective health care burden estimated in multiple billions of dollars annually in the United States alone (1, 3) .
A seemingly insurmountable obstacle in meniscus regeneration, similar to the regeneration of most other complex tissues, is the paucity of viable cells capable of regenerating multiple tissue phenotypes (1) . Heterogeneous populations of connective tissue cells constitute the meniscus including fibroblast-like cells primarily in the outer zone with abundant collagen type I, whereas the inner zone primarily consists of chondrocyte-like cells rich in sulfate glycosaminoglycans (GAGs) and collagen type II (1, 5) . The intermediate zone contains fibrochondrocytes, a cell type that produces both type I and type II collagens (1, 5) . Previous work on meniscus regeneration has revealed that no single-cell source is sufficient to regenerate heterogeneous meniscus tissues (1, 6) . Furthermore, the meniscus is devoid of vascular supply except for the outer zone. The perceived deficiency of vascular-derived stem/progenitor cells is considered a hurdle in meniscus regeneration (2) .
Two acellular biomaterials cleared for human use in Europe appear to relieve pain and symptoms but have yielded inconsistent clinical outcome and reported adverse events including graft shrinkage, problematic attachment and integration into host tissue, and myxoid degeneration (4, 5) . Absent in previous work on the regeneration of the meniscus is fibrocartilage phenotype that needs to be restored for proper meniscus function to withstand both tensile and compressive stresses (4, 5) . The regenerated meniscus tissue should not only restore cell and matrix properties but also perform mechanical functions, analogous to other efforts to regenerate the heart, lungs, kidney, bladder, and bone (7) (8) (9) (10) .
Here, we have devised a three-dimensional (3D)-printed, anatomically correct biomaterial scaffold that can coax endogenous cells to regenerate the meniscus with fibrocartilage tissues in specific zones. The scaffold releases two human proteins in a spatially and temporally controlled manner, leading to the generation of multiple tissue phenotypes, yielding instructive clues for the regeneration of complex tissues in a translational model. The present protein delivery approach seems readily poised for a human clinical trial in which proteins are packaged in a good manufacturing practice (GMP) facility and shipped to hospitals and clinics for patient use.
RESULTS
Sequential growth factor treatment induces fibrochondrocyte differentiation of human mesenchymal stem/progenitor cells in vitro We first derived fibrochondrocyte-like cells-meniscus-resident cells that concurrently produced both type I and type II collagens-from human bone marrow and synovium mesenchymal stem/progenitor cells (MSCs) in vitro. Sequential application of recombinant human connective tissue growth factor (rhCTGF) for 2 weeks in culture, followed by recombinant human transforming growth factor-b3 (rhTGFb3) for 2 weeks (C→T in Fig. 1 and fig. S1 ), induced differentiation of MSCs into cells that synthesized procollagens I and IIa, suggesting that they were fibrochondrocytelike cells, with a yield of 72.22% in monolayer culture and 76.92% in 3D fibrin hydrogels. This yield for C→T was significantly higher than that for the reverse (T→C) and the combination (T+C), both in monolayer culture and in 3D fibrin (Fig. 1A and table S1 ) (Student's t test: P < 0.000001 for C→T versus T→C; P = 0.0032 for C→T versus T+C).
C4 or T4 alone failed to yield fibrochondrocyte-like cells. MSC differentiation into fibrochondrocyte-like cells was attenuated upon reversed sequential treatment with TGFb3 and CTGF (T→C) or either CTGF (C4) or TGFb3 (T4) alone (Fig. 1A and table S1) .
MSCs treated with C→T demonstrated significantly higher collagen I, collagen II, and aggrecan mRNA than the control (untreated MSCs) (Fig. 1, B to D, and table S2). Moreover, C→T not only induced MSC differentiation but also yielded a fibrocartilaginous matrix that stained positively for picrosirius red and alcian blue in both monolayer culture ( fig. S2A ) and 3D fibrin gels ( fig. S3A ), indicating synthesis of both type I and type II collagens, respectively. C→T treatment led to greater GAG Fig. 1 . Sequential rhCTGF and rhTGFb3 treatment of bone marrow MSCs induces fibrochondrocyte differentiation. (A) Immunofluorescence analysis of procollagen I chain (proCOL-I) and procollagen IIa (proCOL-IIa) production by human MSCs treated in culture with C→T (rhCTGF for 2 weeks followed by rhTGFb3 for 2 weeks), T→C (rhTGFb3 for 2 weeks followed by rhCTGF for 2 weeks), C+T (rhCTGF and TGFb3 concurrently for 4 weeks), C4 (rhCTGF alone for 4 weeks), and T4 (rhTGFb3 alone for 4 weeks). Cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). A total of five replicates were tested, with representative images selected. (B to D) Expression of (B) collagen type I (COL-I), (C) collagen type II (COL-II), and (D) aggrecan (AGC) mRNA after MSC exposure to treatments in (A), with the exception that concurrent CTGF and TGFb3 application (C+T) was 4 weeks. Data are averages ± SD (n = 5) normalized to GAPDH, then relative to control. *P < 0.05 between indicated groups; # P < 0.05 versus control; + P < 0.05 versus positive control (C4 for collagen type I or T4 for collagen type II and aggrecan), one-way analysis of variance (ANOVA) with posthoc Tukey' s B test. Complete statistical analysis is in table S2. content than T→C (figs. S2B and S3B), but T→C produced more type II collagen than did C→T (figs. S2C and S3C). However, T→C failed to yield a substantial number of fibrochondrocyte-like cells, thus making this treatment approach unlikely for meniscus regeneration in vivo (Fig. 1) . We found that C→T elevated collagen I expression by fibrochondrocytes primarily via focal adhesion kinase (FAK) signaling, whereas collagen II and aggrecan expression was driven primarily via p38 signaling ( fig. S4) . Collectively, sequential application of rhCTGF and rhTGFb3 was necessary and sufficient to induce fibrochondrogenic differentiation of human MSCs in vitro.
MSCs isolated as mononucleated and adherent cells from bone marrow and other sources are heterogeneous, and typically represent a mix of mature cells such as osteoblasts, fibroblasts, and some stem/ progenitor cells. We therefore performed clonal analysis to ascertain that fibrochondrocytes were derived from progenies of a single MSC. Of 59 randomly selected MSCs from human bone marrow, 29 (∼53%) yielded clonal progenies, such as A5, B6, D7, and H1 ( fig. S5A) , by limiting dilution. About 55% of clonal progenies, including A5 and B6, differentiated into fibrochondrogenic, osteogenic, chondrogenic, and adipogenic cells in corresponding chemically defined medium ( fig. S5B ). Together, MSCs, as a heterogeneous population or as singlecell progenies, can differentiate into cells that concurrently produce type I and II collagens, arguably fibrochondrocytes upon sequential CTGF and TGFb3 application, signifying the need for in vivo testing of fibrocartilage regeneration.
3D printing fabricated human and sheep meniscus scaffolds
We chose to test the dynamic combination of CTGF and TGFb3 in an established knee meniscus injury model (11, 12) , owing to its potential generalizability in the regeneration of complex, inhomogeneous tissues. Anatomically correct human meniscus scaffolds were fabricated using 3D printing (13) . Briefly, poly-ɛ-caprolactone (PCL) was molten to fabricate an anatomically correct meniscus scaffold modeled after a reconstructed human cadaver meniscus ( Fig. 2A) . The 3D-printed human meniscus scaffold was at ∼40% of the real size of a human cadaver meniscus ( Fig. 2A) , so that it fits in a cell culture well for additional experiments. Interlaid strands and interconnecting microchannels (diameters of 100 to 200 mm) were aligned along the circumferential direction as conduits for cellular ingrowth, mimicking the predominant meniscal collagen orientation ( Fig. 2A, inset) (14) and allowing for cells to be metabolically satisfied [within 200 mm of blood vessels, as shown in (15)].
rhCTGF and rhTGFb3 were microencapsulated in PLGA mS, with rhCTGF in 50:50 PLA/PGA mS and rhTGFb3 in 75:25 PLA/PGA mS (Fig.  2B ). CTGF and TGFb3 mS were tethered to the outer and inner regions of the meniscus scaffold, respectively. Physical bonding between proteinencapsulating mS and PCL microfibers was induced by ethanol. To validate multiphase mS distribution, fluorophore-conjugated dextrans with molecular weights similar to rhCTGF (∼40 kD) and rhTGFb3 (∼10 kD) were delivered to the scaffold's outer and inner zones, respectively, at day 1 (Fig. 2C) . At day 8, the distribution of 40-kD dextrans (green) and 10-kD dextrans (red) was maintained. Spheres with 50:50 ratio showed controlled release of CTGF first, followed by TGFb3. Relatively rapid rhCTGF release from the outer layer and slower release of rhTGFb3 from the inner layer were sustained over 42 days (Fig. 2D) .
Before in vivo application of the growth factor-loaded PCL scaffold, we ascertained whether spatiotemporal delivery of rhCTGF and rhTGFb3 induced zone-specific MSC differentiation into cells that produced type I and II collagens. Porous meniscus scaffolds incorporating rhCTGF and rhTGFb3 for spatiotemporally controlled release were placed atop monolayer-cultured human synovium MSCs. After a 6-week incubation period in vitro, spatiotemporally released rhCTGF and rhTGFb3 induced zone-specific expression of collagen types I and II, presumably from the differentiated synovium MSCs, with resemblance to the native rat meniscus (Fig. 2E ). Abundant collagen type I was present primarily in the outer zone (picrosirius red-positive), whereas cartilaginous matrix with collagen type II was primarily in the inner zone (alcian blue-positive) (Fig. 2F) . A mixed fibrocartilaginous matrix developed in the intermediate zone (Fig. 2F ).
Spatially released CTGF and TGFb3 from 3D-printed scaffolds led to regeneration of sheep knee meniscus We aimed to regenerate the sheep meniscus in vivo by spatiotemporal release of rhCTGF and rhTGFb3 in anatomically correct PCL scaffolds. Sheep is a widely used preclinical model for meniscus regeneration owing to its similarity to humans in vascular supply, anatomy, and biochemical composition (16) . The native sheep medial meniscus was laser-scanned for the fabrication of total or partial meniscus scaffold (Fig. 3A) , followed by spatial rhCTGF and rhTGFb3 incorporation as described above.
Before in vivo implantation, the scaffold's internal microstructure was optimized to yield mechanical properties similar to those of the native sheep meniscus. Among 50-to 500-mm interlaid strands and interstrand microchannels, diameters of 200 and 100 mm were selected because they yielded dynamic compressive modulus (E*), storage modulus (E′), and loss modulus (E″) similar to the intermediate zone of the native sheep meniscus (Fig. 3B ). Pull-out tests were performed in harvested sheep cadavers after partial meniscectomy and suture fixation ( fig. S6 ). The maximum pull-out strength of the scaffold-toouter rim of the native meniscus was significantly higher than the native partial meniscus grafts-to-outer rims (54.5 N versus 39.8 N) ( Fig. 3C and fig. S6 ). The equilibrium friction coefficient on angular velocity (0.01 to 1 rad/s) of the optimized scaffold was similar to the native meniscus (Fig. 3D) .
A total of 11 skeletally mature (2-to 5-year-old) sheep were randomly allocated into control (scaffold only with empty mS; n = 4) and treatment (spatiotemporal rhCTGF and rhTGFb3 delivery; n = 7) groups. We used partial meniscus grafting (Fig. 3A) owing to high clinical rates of partial meniscectomy (1, 2). Anatomically correct meniscus scaffolds were implanted after partial meniscectomy (Fig. 3E) . Briefly, the medial meniscus was exposed after femoral condylectomy. With all ligaments preserved, ∼80% medial meniscus was resected including the inner, intermediate, and a major portion of the outer zone, followed by replacement with anatomically correct partial meniscus scaffolds. The meniscus scaffold was sutured to the remaining ∼20% outer rim of the native meniscus. Twelve weeks after implantation, the scaffold integrated fully into the remaining outer rim of the meniscus, with no notable damage to articular cartilage in either the femoral or tibial condyle (Fig. 3F) .
The native sheep meniscus showed a characteristic pattern of extracellular matrix distribution with fibroblast-like cells among collagen bundles in the outer zone, cartilage-like tissue in the inner zone, and a mixed fibrous and cartilage tissue in the intermediate zone (Fig. 4A ). Spatiotemporal delivery of CTGF and TGFb3 from the implanted scaffolds yielded native-like fibrocartilage: a collagen-rich, aligned fibrous matrix in the outer zone; a fibrocartilaginous matrix in the intermediate zone; and a cartilaginous matrix in the inner zone (Fig. 4B) , resembling the zonal matrix characteristics of the native sheep meniscus. Sheep menisci replaced with anatomically correct scaffolds encapsulating empty mS showed amorphous fibrous tissue throughout, without zone-specific tissue phenotypes (Fig. 4C) .
The regenerated meniscus tissue showed zone-specific cell phenotypes similar to the native meniscus (Fig. 4D) . The outer zone of the regenerated meniscus was populated by fibroblast-like, spindle-shaped (Fig. 4E) .
The regenerated knee meniscus restored biomechanical and functional properties All sheep undergoing operation resumed weight bearing and locomotion as early as 3 weeks after surgery. A sheep that received a CTGF→TGFb3 mS-laden scaffold in the medial meniscus of the left knee demonstrated fully restored locomotion and weight bearing at 6 weeks post-op (movie S1), whereas a sheep that received an anatomically correct scaffold but with empty mS is shown in movie S2. Both sheep were able to resume locomotion and weight bearing. However, CTGF→TGFb3 delivery not only yielded zone-specific fibrocartilage tissue phenotype (Fig. 4B ) but also restored mechanical properties of the regenerated fibrocartilage tissue.
Instantaneous modulus (E i ), relaxation modulus (E r ), and viscosity (m) were measured by fitting to a Kelvin solid viscoelastic model (17, 18). E i , E r , and m of the native meniscus showed inhomogeneity along the radial zone, which includes the outer, intermediate, and inner zones of meniscus (Fig. 5) , likely owing to multiphase distribution of collagen and GAGs in the meniscus (17, 18) . The CTGF→TGFb3 delivery group yielded E i , E r , and m similar to the native meniscus [P > 0.05, one-way ANOVA; post-hoc least significant difference (LSD)] (Fig. 5A) . Contrastingly, the viscoelastic properties of the empty mS group were inferior to those of the CTGF→TGFb3 mS group or the native menisci (Fig. 5A ).
Young's modulus and ultimate strength from tensile testing at 1%/s (17) were significantly higher in the CTGF→TGFb3 scaffold group and the native menisci than in the empty mS group (Fig. 5B) . The ultimate strain showed no significant differences between the regenerated and native menisci (Fig. 5B) .
DISCUSSION
These findings show that meniscus regeneration with inhomogeneous tissue properties and functional recovery is possible with a protein-releasing, acellular biomaterial scaffold. In contrast to cell transplantation, the present strategy of endogenous regeneration upon spatiotemporal release of two recombinant human proteins offers a ready-to-implant graft that may serve as a therapeutic prototype. Regeneration by cell homing, now being sporadically demonstrated in several tissue/organ systems (12, 13, 19) , provides an alternative to cell transplantation. Biologically, regeneration by cell transplantation or cell homing is not mutually exclusive. Transplanted cells secrete cytokines that promote the survival, cell recruitment, or differentiation of host endogenous cells (20) . However, regeneration by cell homing circumvents the need for ex vivo cell culture. Endogenous cells that have migrated to a healing wound are likely those with the ability to survive in situ. Contrastingly, en mass transplanted cells are exposed to an environment that may not be primed for cell vitality (20, 21) . Further, transplantation of parenchymal cells, which is typical of all cell delivery approaches, must rely on the recruitment of endogenous stromal cells for the generation of a complete tissue. Recently, growth factor binding was shown to be a primary mechanism of action of fibrin in diabetic wound repair without cell transplantation (22) .
How recruited endogenous cells, including stem/progenitor cells, or transplanted parenchymal cells orchestrate stromal as well as vascular, neural, lymphatic, and immune components in a restored tissue warrants further investigation. Here, a fibrochondrocyte phenotype was derived from MSCs when CTGF and TGFb3 were sequentially applied in vitro or spatiotemporally released in vivo. FAK and p38 pathways have been implicated in collagen and aggrecan synthesis, and hence were studied here. Our initial data suggest that C→T elevates collagen I mRNA expression primarily via FAK signaling, whereas collagen II and aggrecan mRNA expression was increased primarily via p38 signaling. Such preliminary signaling studies could yield clues for additional targets in enhancing meniscus regeneration.
Despite precise and reproducible in vitro CTGF and TGFb3 release kinetics that led to fibrochondrogenic phenotype, in vivo actions of released proteins and peptides are best judged by the quality of the tissue they are intended to regenerate (23, 24) , in this case, a consistent yield of fibrocartilage in vivo. Meniscus regeneration demands not only restoration of biological structures at cell and matrix levels but also the capacity to exert mechanical functions, analogous to the regeneration of the heart, lungs, kidney, bladder, and blood vessels (7) (8) (9) . Inhomogeneity is characteristic of many biological tissues and all organs. No previous reports to our knowledge have shown functional regeneration or restoration of heterogeneous meniscal tissue phenotypes (16, (25) (26) (27) (28) (29) , although some studies have shown partial healing with somewhat homogeneous tissue or pain relief in large animal models or patients (4, 5) .
The present study reports regeneration of an inhomogeneous, functional knee meniscus in a large animal model with 3-month follow-up. Longer-term evaluation will be needed to assess whether zone-specific tissue phenotypes are sustained with daily function. Our previous work showed reconstitution of a single, uniform tissue-albeit fibrous tissueby in vivo delivery of CTGF alone (12) or articular cartilage upon in vivo delivery of TGFb3 alone (13) . Cell sources for the observed meniscus regeneration may derive from synovium stem/progenitor cells in the wound (30) and also from the remaining ∼20% native, vascularized meniscus tissue (2) , suggesting that perhaps vascular-derived stem/progenitor cells are recruited by appropriate molecules. Previous work has shown the validity of dual growth factors in the formation of a singular neovascular network (31) .
A drawback of a large animal model is its impossibility to delineate cell sources by cell tracing/tracking approaches that are available in transgenic mice (32) . The sheep model also does not permit broad immunophenotyping of regenerated tissues owing to a paucity of antibodies and probes. Although we were unable to track cell recruitment in the sheep, host cell recruitment was demonstrated in a 50% rat meniscus resection defect when LacZ + cells in BMP7-treated Achilles tendon allograft were transplanted (33, 34) , which supports our hypothesis of meniscus regeneration by endogenous cells.
For translation, we envision a 3D-printed human meniscus-shaped material scaffold where both recombinant human proteins, rhCTGF and rhTGFb3, are tethered in the scaffold's microchannels and packaged in a GMP/GLP (good laboratory practice) facility. The packaged products are shipped to hospitals and clinics where meniscus replacement surgeries are performed. The surgeons replace injured menisci using the existing arthroscopy procedure with an off-the-shelf meniscus scaffold rather than the current allograft from cadaver meniscus. Reproducible derivation of fibrochondrocytes from postnatal MSCs by CTGF and TGFb3 may have broad implications in the regeneration of other fibrocartilage tissues, including the intervertebral disc of the spine, the tendon-bone junction, and the temporomandibular joint, each of which, when diseased, is a severe health care burden.
METHODS

Study design
The overall objective and design of the study was to determine whether endogenous cells, including stem/progenitor cells, can be differentiated in situ to regenerate complex tissues, specifically the knee meniscus. The primary parameters of study design included (i) extracellular matrix synthesis and expression of aggrecan, GAGs, and collagen types I and II, which collectively are macromolecules in the native meniscus; (ii) clonogenicity of bone marrow and synovium MSCs; (iii) differentiation capacity of bone marrow and synovium MSCs at population and clonal levels; (iv) mechanical properties of scaffold material including pull-out tests; and (v) mechanical properties of regenerated tissues.
The ability of the acellular, growth factor-releasing material to regenerate fibrocartilage was investigated in vivo in an ovine model. A power analysis was performed before our preclinical, large animal study, as described below. The original sample size was five for the control group and eight for the treated group. A total of 13 sheep were operated on, with 11 reaching end points (n = 4 for control; n = 7 for treated). Two sheep were lost because of anesthesia and surgical complications. The treatment was randomized and blinded from team members who performed the surgeries and postsurgical care. End points were predefined as the presence or absence of statistically significant differences of the above-listed parameters. No outliers were eliminated.
MSC isolation and fibrochondrogenic differentiation
Human MSCs were isolated from commercially available, fresh whole bone marrow samples or surgically removed synovium of anonymous adult donors (age range, 20 to 25 years) per our previous methods (12, 13) . Passage 2/3 MSCs (100,000 cells per well) were plated in six-well culture plates, or 3D pellets were formed by centrifuging 2 × 10 6 MSCs in 15-ml conical tubes. Monolayered cells or cell pellets were treated with (i) CTGF (100 ng/ml) (BioVendor) for 2 weeks followed by TGFb3 (10 ng/ml) (R&D Systems) (C→T); (ii) TGFb3 (10 ng/ml) for 2 weeks followed by CTGF (100 ng/ml) for 2 weeks (T→C); (iii) mixture of CTGF (100 ng/ml) and TGFb3 (10 ng/ml) for 4 weeks (C+T); or (iv) CTGF for 4 weeks (C4), TGFb3 for 4 weeks (T4), and growth medium as a control (Fig. 1) . Fibrochondrogenic induction supplement [ascorbic acids (50 mg/ml)] and chondrogenic induction supplements [1% 1× ITS+1 solution, sodium pyruvate (100 mg/ml), L-ascorbic acid 2-phosphate (50 mg/ml), L-proline (40 mg/ml), 0.1 mM dexamethasone] were included in the CTGF and TGFb3 treatments, respectively (12) .
After 4 weeks of treatment, harvested samples (monolayers and pellet sections) were stained with alcian blue and picrosirius red per our previous methods (12) . GAGs and types I and II collagen were quantitatively assayed (Biocolor) and normalized to DNA content (12) . Immunofluorescence was performed to identify cells expressing proCOL-I (ab64409) and/or proCOL-IIa (ab17771), both from Abcam.
Cellular cloning MSC clones were established by limiting dilution (12) . Briefly, passage 0 MSCs were suspended at a concentration of one cell per 200 ml and seeded in 96-well plates with 200 ml of regular growth medium per well. After 24 hours, wells with only one cell were marked ( fig. S5 ) and maintained in culture at 37°C and 5% CO 2 , with medium change every 3 to 4 days. After 3 to 4 weeks, single-cell-derived clonal progenies were treated with 0.25% trypsin-EDTA and seeded into 24-well plates. Clonal progenies were transferred to six-well plates upon ∼80% confluence and maintained with medium change every 3 to 4 days. Established clones were induced for multilineage differentiation into osteogenic, chondrogenic, and adipogenic lineages per our previous methods (12) , and fibrochondrogenic lineage as described above ( fig. S5 ).
Design and synthesis of anatomically correct meniscus scaffolds Anatomically correct meniscus scaffolds were fabricated using 3D-Bioplotter (EnvisionTEC) per our previous work (13) . Briefly, the anatomic contour of the medial meniscus of human or skeletally mature sheep was captured by multislice laser scanning and reconstructed by computer-aided design. PCL (molecular weight, ∼65,000; Sigma) was molten at 120°C and dispensed, following the layer path dictated by 3D design of internal microstructures. For the human meniscus scaffold, interlaid strands and interconnecting microchannels had a diameter of 100 mm, and circumferentially aligned fibers were added to recapitulate predominant collagen orientation in the native meniscus ( Fig. 2A) . For the sheep meniscus scaffold (Fig. 3A) , 300-mm microstrands and 100-mm microchannels were determined to be optimal (Fig. 3A) to approximate mechanical properties of the native meniscus.
Spatiotemporal CTGF and TGFb3 delivery
Recombinant human CTGF and TGFb3 were encapsulated in 50:50 and 75:25 (PLA/PGA) mS, respectively, using double emulsion (12) . Two different PLGA ratios were applied to yield controlled CTGF and TGFb3 release. Briefly, a total of 250 mg of PLGA was dissolved into 1 ml of dichloromethane. CTGF (10 mg) or TGFb3 (2.5 mg) was diluted to 50 ml following the manufacturer's protocols and added to the PLGA solution, forming a mixture (primary emulsion) that was emulsified for 1 min (water-in-oil). The primary emulsion was then added to 2 ml of 1% polyvinyl alcohol (PVA; molecular weight, 30,000 to 70,000), followed by 1-min mixing [(water-in-oil)-in-water]. Upon adding 100 ml of PVA, the mixture was stirred for 1 min at room temperature. A total of 100 ml of 2% isopropanol was added to the final emulsion and continuously stirred for 2 hours to remove the solvent. Control microspheres (empty, without CTGF or TGFb3, reflecting a mixture of both 75:25 and 50:50 PLA/PGA) were fabricated with 50 ml of distilled water. Release kinetics of CTGF and TGFb3 from PLGA mS were measured by incubating microspheres (10 mg/ml) encapsulating CTGF [in phosphate-buffered saline (PBS)] or TGFb3 (0.1% bovine serum albumin) at 37°C with mild agitation for up to 42 days (12) . Upon centrifugation at 2500 rpm for 5 min, supernatant of the PLGA mS incubation solution was collected. Released CTGF and TGFb3 concentration was measured using enzyme-linked immunosorbent assay (ELISA) kits following the manufacturer's protocols.
PLGA mS (10 mg/ml) containing either CTGF or TGFb3 were then incorporated on scaffold's microstrands by ethanol treatment for 1 hour (35) . CTGF-encapsulated mS were applied in the microchannels in the scaffold's outer/middle zones, whereas TGFb3-encapsulated mS were applied in inner/middle zones. Multiphase distribution of CTGF and TGFb3 mS was validated by incorporating mS-encapsulating fluoresceinconjugated dextran (40 kD) and Alexa Fluor 546 dextran (10 kD), representing CTGF and TGFb3, respectively. Dextran distribution was visualized using Maestro (PerkinElmer). Upon fibrin gel infusion into microchannels, scaffolds with dextran-encapsulated mS were incubated at 37°C for 8 days and imaged with Maestro.
In vitro cell recruitment and tissue synthesis
The anatomically correct meniscus scaffolds with spatiotemporal delivery of CTGF-TGFb3 were placed on top of monolayer cultured human synovium MSCs (100,000 per well) in a six-well plate. After 6 weeks of culture with a mixture of fibrogenic and chondrogenic supplemented medium, the scaffolds were harvested and analyzed for cell recruitment and zone-specific tissue formation. Cell recruitment was confirmed by DAPI staining in the scaffolds, and tissue formation was evaluated by histology and immunofluorescence.
Meniscectomy and grafting A total of 11 sheep were randomly allocated into treated (n = 7) and control (n = 4) groups. A medial parapatellar approach was made through the skin and subcutaneous tissue. A lateral parapatellar arthrotomy was performed, and the patella was luxated medially. After flexing of the joint and exposure of the medial meniscus, condylectomy was performed using an oscillating saw from the axial side of the medial femoral condyle toward the distal medial femoral metaphysis. All the associated joint ligaments were preserved. Then, a partial meniscectomy was performed by resecting all but ∼20% of the meniscus' outer zone and immediately grafted with anatomically correct meniscus scaffold, followed by suturing (2-0 Ethibond Excel, Braided). Condylectomy was repaired with 2-or 4.5-mm-diameter cortical bone screws. The joint capsule and subcutaneous tissue were closed separately in continuous absorbable suture. The skin was staple-closed and covered with a sterile bandage.
The operated sheep were confined to small pens (4 × 4 ft 2 ) to minimize sudden or extended movements. Sheep were in direct visual, vocal, and nasal contact with each other, but were in separate pens to minimize inadvertent trauma. Pain medication (narcotics and nonsteroidal anti-inflammatory drugs) was administered intramuscularly for a minimum of 2 weeks post-op. Upon complete condylectomy healing on radiographs, sheep were group-housed in a small paddock (six sheep per 12 × 12 ft 2 paddock) for 1 week for acclimation and then transferred to a large paddock (96 × 96 ft 2 ) until euthanasia. All in vivo samples were harvested at 12 weeks post-op. Harvested tissue was fixed in 4% formaldehyde, embedded in paraffin, and cut in 5-mm sections.
Mechanical tests
Four of seven treated samples were selected for mechanical testing. The other three samples were used for tissue-based analyses.
Dynamic compression. Before in vivo implantation, dynamic compression was performed to match scaffold's mechanical properties with those of the native meniscus (13) . Briefly, cylindrical plugs were punched from the central regions of scaffolds and native meniscus (5 × 5 mm 2 ) (n = 5 per group). Compressive testing was performed under 10% cyclic strain at 2 Hz, and dynamic compressive properties were characterized as complex compressive modulus E*, storage modulus E′, and loss modulus E″. All mechanical tests were performed using ElectroForce BioDynamic testing system (Bose).
Pull-out strength. About 75% of the sheep medial meniscus was longitudinally cut with a scalpel. A total of four holding sutures (2-0 Ethibond Excel, Braided) were placed between the inner and outer portions of the meniscus and the scaffold. The maximum pull-out force was measured after mounting the samples using stainless steel wired on ElectroForce tensile grips and pulled at 0.5 mm/s (36) .
Friction coefficient. Equilibrium friction coefficients, meq, on angular velocity were measured to estimate the scaffold's frictional property (19) . Cylindrical samples (10-mm diameter × 3-mm thickness), prepared from the middle region of menisci and scaffolds, were fixed to an impermeable bottom platen using cyanoacrylate glue and immersed in a PBS bath. After 5% compressive tare strain for 1800 s, a series of sequential angular velocities (0.01, 0.1, and 1 rad/s) were applied for 120 s each. Friction coefficient (m eq ) was calculated as friction force (F) divided by normal force (N). With an assumption of zero unknown frictional shear at the center and linear distribution along with the radial direction, the average frictional force, F, was obtained as F = 4T/3r 0 , where T is the frictional torque and r 0 was the specimen's radius.
Stress relaxation. Disc-shaped samples (5-mm diameter × 2-mm thickness) were prepared from the inner, middle, and outer regions of the native and regenerated menisci. Using unconfined compression, samples were preconditioned with 15 cycles of 0 to 5% compressive strain, followed by stress relaxation with 20% compressive strain. A Kelvin standard solid viscoelastic model was applied to calculate instantaneous modulus (E i ), modulus of relaxation (E r ), and viscosity (m) (19, 24) .
Tensile test. Circumferential strips of the middle region of the native and regenerated menisci were cut into dog bone shapes 25 mm in length and 1 mm in average thickness per previous methods (19, 24) . After preconditioning of 15 cycles of 0 to 2% strain, tensile tests were performed at 1% strain per second. The linear portion of each stressstrain curve was used to determine the Young's modulus (E y ). The ultimate strength and strain was determined from each curve.
Data analysis and statistics
Sample sizes for all quantitative data were determined by power analysis with one-way ANOVA using an a level of 0.05, power of 0.8, and effect size of 1.50 chosen to assess matrix synthesis, gene expressions, and mechanical properties in the regenerated meniscus tissues and controls upon verification of normal data distribution. In case of skewed data distribution, a nonparametric test, Kruskal-Wallis one-way ANOVA, will be performed using an a level of 0.05, power of 0.8, and effect size of 1.50. Analysis using PASS (NCSS) indicated necessary sample sizes of four to seven to achieve a power value of 0.8 for the in vitro and in vivo parameters used in the present study. Expected SD and means were entered on the basis of our previous work for meniscus tissue regeneration and MSC differentiations (13) . Briefly, f analysis was performed with estimated means and SDs of control and test groups using the following equation: 
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/6/266/266ra171/DC1 Fig. S1 . Fibrochondrogenic differentiation of human bone marrow MSCs in 3D fibrin. Fig. S2 . Fibrochondrogenic matrix production by fibrochondrocytes derived from human MSCs in monolayer culture. Fig. S3 . Fibrochondrogenic matrix production by fibrochondrocytes derived from human MSCs in 3D fibrin gel. Fig. S4 . FAK and p38 signaling plays a role in collagen and aggrecan expression after fibrochondrocyte differentiation in vitro. Fig. S5 . Single-cell progenies of human bone marrow MSCs differentiate into fibrochondrocytes. Fig. S6 . Mechanical testing of scaffold to meniscus and partially resected meniscus. Table S1 . Fibrochondrocyte differentiation from human bone marrow MSCs in monolayer and 3D cultures. Table S2 . Statistical significances for comparisons in between groups in Fig. 1, fig. S2, and fig S3. Movie S1. Sheep movement after medial meniscus replacement with 3D-printed scaffold with spatial CTGF and TGFb3 delivery. Movie S2. Sheep movement after medial meniscus replacement with 3D-printed scaffold with empty mS.
